Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Protriptyline
Drug ID BADD_D01872
Description Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, alpha1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
Indications and Usage For the treatment of depression.
Marketing Status Prescription; Discontinued
ATC Code N06AA11
DrugBank ID DB00344
KEGG ID D08447
MeSH ID D011530
PubChem ID 4976
TTD Drug ID D00MYQ
NDC Product Code Not Available
Synonyms Protriptyline | Vivactil | Protriptyline Hydrochloride | Hydrochloride, Protriptyline
Chemical Information
Molecular Formula C19H21N
CAS Registry Number 438-60-8
SMILES CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Parotid gland enlargement07.06.03.001--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Testicular swelling21.13.01.003--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue discolouration07.14.02.006--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages